295 related articles for article (PubMed ID: 20714888)
21. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction.
Fujioka K
JAAPA; 2007 Dec; Suppl():3-8. PubMed ID: 18217245
[TBL] [Abstract][Full Text] [Related]
22. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.
Kuhre RE; Wewer Albrechtsen NJ; Hartmann B; Deacon CF; Holst JJ
J Diabetes Complications; 2015 Apr; 29(3):445-50. PubMed ID: 25623632
[TBL] [Abstract][Full Text] [Related]
23. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
Matuszek B; Lenart-Lipińska M; Nowakowski A
Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
[TBL] [Abstract][Full Text] [Related]
24. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
25. Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes.
Marathe CS; Rayner CK; Bound M; Checklin H; Standfield S; Wishart J; Lange K; Jones KL; Horowitz M
Diabetes; 2014 Aug; 63(8):2668-75. PubMed ID: 24696447
[TBL] [Abstract][Full Text] [Related]
26. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
27. Diabetes remission after bariatric surgery: is it just the incretins?
Laferrère B
Int J Obes (Lond); 2011 Sep; 35 Suppl 3(0 3):S22-5. PubMed ID: 21912382
[TBL] [Abstract][Full Text] [Related]
28. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
29. Incretin effect: GLP-1, GIP, DPP4.
Kazafeos K
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
[TBL] [Abstract][Full Text] [Related]
30. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.
Gribble FM
Diabet Med; 2008 Aug; 25(8):889-94. PubMed ID: 18959599
[TBL] [Abstract][Full Text] [Related]
31. Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus.
Nasr NE; Sadek KM
Environ Sci Pollut Res Int; 2022 Mar; 29(13):18408-18422. PubMed ID: 35031999
[TBL] [Abstract][Full Text] [Related]
32. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
33. Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis.
Mezza T; Moffa S; Ferraro PM; Quero G; Capece U; Carfì A; Cefalo CMA; Cinti F; Sorice GP; Impronta F; Mari A; Pontecorvi A; Alfieri S; Holst JJ; Giaccari A
J Clin Endocrinol Metab; 2019 Jul; 104(7):2685-2694. PubMed ID: 30874733
[TBL] [Abstract][Full Text] [Related]
34. Pleiotropic effects of GIP on islet function involve osteopontin.
Lyssenko V; Eliasson L; Kotova O; Pilgaard K; Wierup N; Salehi A; Wendt A; Jonsson A; De Marinis YZ; Berglund LM; Taneera J; Balhuizen A; Hansson O; Osmark P; Dunér P; Brøns C; Stancáková A; Kuusisto J; Bugliani M; Saxena R; Ahlqvist E; Kieffer TJ; Tuomi T; Isomaa B; Melander O; Sonestedt E; Orho-Melander M; Nilsson P; Bonetti S; Bonadonna R; Miccoli R; Delprato S; Marchetti P; Madsbad S; Poulsen P; Vaag A; Laakso M; Gomez MF; Groop L
Diabetes; 2011 Sep; 60(9):2424-33. PubMed ID: 21810601
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.
Mentlein R
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):443-52. PubMed ID: 19748062
[TBL] [Abstract][Full Text] [Related]
36. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
João AL; Reis F; Fernandes R
Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
[TBL] [Abstract][Full Text] [Related]
37. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action.
Villareal DT; Robertson H; Bell GI; Patterson BW; Tran H; Wice B; Polonsky KS
Diabetes; 2010 Feb; 59(2):479-85. PubMed ID: 19934000
[TBL] [Abstract][Full Text] [Related]
38. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
[TBL] [Abstract][Full Text] [Related]
39. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
40. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance.
Sheikh S; Gudipaty L; De Leon DD; Hadjiliadis D; Kubrak C; Rosenfeld NK; Nyirjesy SC; Peleckis AJ; Malik S; Stefanovski D; Cuchel M; Rubenstein RC; Kelly A; Rickels MR
Diabetes; 2017 Jan; 66(1):134-144. PubMed ID: 27495225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
